What are GLP-1 medications like semaglutide and tirzepatide?

They are once-weekly injectable drugs proven to support significant weight loss and improve metabolic health.

How much weight can you lose with semaglutide or tirzepatide?

Clinical studies show average weight loss of 14–17% of total body weight after one year—with some patients achieving more.

In the U.S., adult obesity is down in 2025, partly due to expanded use of weight loss medications.

Best results come from medical supervision using FDA-approved medications, nutrition counseling, and ongoing support.

Posted at 11:06h in Medical Weight Loss by Skinny

Table of Contents

12.4% of U.S. adults have tried GLP-1 medications like semaglutide or tirzepatide for weight loss as of Q3 2025 (CBS News).
Real-world studies show average weight loss of 14–17% after one year on semaglutide 2.4mg or tirzepatide, with mean reductions of 14.6–17.2 kg (PubMed).
Tirzepatide prescription rates increased 32% in early 2025, with 1.3% of all U.S. prescriptions; semaglutide now 0.7% (Truveta).
Clinical trials suggest tirzepatide has even greater weight loss potential than semaglutide (NCBI PMC).
Access barriers remain: Only 49.2% of first-time GLP-1 prescriptions for weight loss are filled within 60 days, often due to cost/insurance (Truveta).

U.S. adult obesity has declined to 37% in 2025 (from a record 39.9% in 2022), marking 7.6 million fewer obese adults (Gallup).
Global obesity is on pace to reach nearly 1 billion adults by the end of 2025 (Obesity Tech, World Obesity Atlas).
Childhood obesity has doubled to 390 million globally between 2020–2025 (Obesity Tech).
Obesity prevalence remains highest among Black (49.9%) and Hispanic (45.6%) Americans (Obesity Tech).
U.S. adult diabetes rate reached an all-time-high of 13.8% in 2025 (Gallup).

Annual probability of achieving at least 5% weight loss with modern medical support (including GLP-1s) is about 18–23% (JAMA).
For semaglutide, 8 in 10 users reach the max effective dose; tirzepatide, 1 in 4 reach max dose in one year (PubMed).
Clinical trial data: Average patient on tirzepatide or semaglutide loses 30+ lbs in 52 weeks (PubMed).
Bariatric surgery produces highest long-term loss (93% achieve ≥5% loss in a year), but carries higher risk and cost (JAMA).
60% of U.S. adults with obesity attempted to lose weight in the past year (JAMA).

Obesity rates: Rural U.S. much higher than urban (March 2025 data) (USDA ERS).
Black and Hispanic Americans face systemic barriers (food deserts, healthcare inequities) (Obesity Tech).
Only 7% of counties globally are prepared for rising obesity trends (World Obesity Federation).
Women are slightly more likely to use injectable weight loss medications than men in all age groups (PubMed).

Over 1.6 million preventable deaths per year globally are caused by overweight/obesity (World Obesity Atlas).
Obesity and overweight remain top causes for Type 2 diabetes, some cancers, heart disease, and stroke (Gallup).
Combined medical and productivity costs of obesity projected at $2 trillion in 2025 (Obesity Tech).

What are GLP-1 medications like semaglutide and tirzepatide?: They are once-weekly injectable drugs proven to support significant weight loss and improve metabolic health.
How much weight can you lose with semaglutide or tirzepatide?: Clinical studies show average weight loss of 14–17% of total body weight after one year—with some patients achieving more.
Is obesity finally declining?: In the U.S., adult obesity is down in 2025, partly due to expanded use of weight loss medications.
What is the safest, most effective way to lose weight?: Best results come from medical supervision using FDA-approved medications, nutrition counseling, and ongoing support.

Sources:
Gallup, CBS News, Truveta, Obesity Tech, PubMed, World Obesity Atlas, JAMA